CN112111007A - Preparation method of novel coronavirus nucleocapsid protein monoclonal antibody - Google Patents
Preparation method of novel coronavirus nucleocapsid protein monoclonal antibody Download PDFInfo
- Publication number
- CN112111007A CN112111007A CN202011002612.6A CN202011002612A CN112111007A CN 112111007 A CN112111007 A CN 112111007A CN 202011002612 A CN202011002612 A CN 202011002612A CN 112111007 A CN112111007 A CN 112111007A
- Authority
- CN
- China
- Prior art keywords
- klh
- solution
- mixed solution
- screening
- monoclonal antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 108700002099 Coronavirus Nucleocapsid Proteins Proteins 0.000 title claims abstract description 16
- 238000012216 screening Methods 0.000 claims abstract description 54
- 239000000427 antigen Substances 0.000 claims abstract description 42
- 102000036639 antigens Human genes 0.000 claims abstract description 42
- 108091007433 antigens Proteins 0.000 claims abstract description 42
- 229920001184 polypeptide Polymers 0.000 claims abstract description 42
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 42
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 42
- 230000002163 immunogen Effects 0.000 claims abstract description 30
- 101710141454 Nucleoprotein Proteins 0.000 claims abstract description 28
- 238000001514 detection method Methods 0.000 claims abstract description 28
- 230000003053 immunization Effects 0.000 claims abstract description 19
- 238000000034 method Methods 0.000 claims abstract description 17
- 102000014914 Carrier Proteins Human genes 0.000 claims abstract description 9
- 108010078791 Carrier Proteins Proteins 0.000 claims abstract description 9
- 230000008878 coupling Effects 0.000 claims abstract description 9
- 238000010168 coupling process Methods 0.000 claims abstract description 9
- 238000005859 coupling reaction Methods 0.000 claims abstract description 9
- 230000002194 synthesizing effect Effects 0.000 claims abstract description 8
- 241001465754 Metazoa Species 0.000 claims abstract description 6
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 5
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 5
- 239000011259 mixed solution Substances 0.000 claims description 72
- 239000000243 solution Substances 0.000 claims description 47
- 210000004027 cell Anatomy 0.000 claims description 36
- 238000002965 ELISA Methods 0.000 claims description 28
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 claims description 22
- 241000699670 Mus sp. Species 0.000 claims description 21
- 238000002156 mixing Methods 0.000 claims description 20
- 102000004190 Enzymes Human genes 0.000 claims description 17
- 108090000790 Enzymes Proteins 0.000 claims description 17
- 230000007910 cell fusion Effects 0.000 claims description 16
- 210000000952 spleen Anatomy 0.000 claims description 16
- 238000002649 immunization Methods 0.000 claims description 15
- 239000006228 supernatant Substances 0.000 claims description 15
- 238000012258 culturing Methods 0.000 claims description 14
- 210000004408 hybridoma Anatomy 0.000 claims description 13
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 12
- 239000002671 adjuvant Substances 0.000 claims description 12
- 239000007853 buffer solution Substances 0.000 claims description 12
- 238000005406 washing Methods 0.000 claims description 12
- 238000004113 cell culture Methods 0.000 claims description 11
- 239000006285 cell suspension Substances 0.000 claims description 11
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 11
- 239000011248 coating agent Substances 0.000 claims description 10
- 238000000576 coating method Methods 0.000 claims description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 claims description 9
- 238000000502 dialysis Methods 0.000 claims description 9
- 238000007789 sealing Methods 0.000 claims description 9
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 9
- 239000012279 sodium borohydride Substances 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 8
- 108090001074 Nucleocapsid Proteins Proteins 0.000 claims description 8
- 239000013604 expression vector Substances 0.000 claims description 8
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 6
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 239000012228 culture supernatant Substances 0.000 claims description 6
- 239000008367 deionised water Substances 0.000 claims description 6
- 229910021641 deionized water Inorganic materials 0.000 claims description 6
- 238000000855 fermentation Methods 0.000 claims description 6
- 230000004151 fermentation Effects 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 6
- 239000008055 phosphate buffer solution Substances 0.000 claims description 6
- 239000000758 substrate Substances 0.000 claims description 6
- 239000011534 wash buffer Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 5
- 230000004927 fusion Effects 0.000 claims description 5
- 230000016784 immunoglobulin production Effects 0.000 claims description 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 4
- 238000011534 incubation Methods 0.000 claims description 4
- 230000009465 prokaryotic expression Effects 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 3
- 241000283707 Capra Species 0.000 claims description 3
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims description 3
- 239000004677 Nylon Substances 0.000 claims description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 3
- 230000003213 activating effect Effects 0.000 claims description 3
- 238000001261 affinity purification Methods 0.000 claims description 3
- -1 ammonium ions Chemical class 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims description 3
- 230000008859 change Effects 0.000 claims description 3
- 238000010367 cloning Methods 0.000 claims description 3
- 238000003113 dilution method Methods 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 238000011049 filling Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 238000007037 hydroformylation reaction Methods 0.000 claims description 3
- 229920001778 nylon Polymers 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 3
- 239000007974 sodium acetate buffer Substances 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 239000012089 stop solution Substances 0.000 claims description 3
- 238000010254 subcutaneous injection Methods 0.000 claims description 3
- 239000007929 subcutaneous injection Substances 0.000 claims description 3
- 230000009471 action Effects 0.000 claims description 2
- 238000007710 freezing Methods 0.000 claims description 2
- 230000008014 freezing Effects 0.000 claims description 2
- 238000007747 plating Methods 0.000 claims description 2
- 210000004988 splenocyte Anatomy 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 241000711573 Coronaviridae Species 0.000 abstract description 9
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract description 2
- 230000008569 process Effects 0.000 abstract description 2
- 206010035664 Pneumonia Diseases 0.000 description 3
- 241001678559 COVID-19 virus Species 0.000 description 2
- 208000006083 Hypokinesia Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000001528 Coronaviridae Infections Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010035737 Pneumonia viral Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 238000011841 epidemiological investigation Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 208000009421 viral pneumonia Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The invention discloses a preparation method of a novel coronavirus nucleocapsid protein monoclonal antibody, which comprises the following steps: synthesizing S1 polypeptide, preparing S2 immunogen, preparing and screening antigen by S3, immunizing S4 animals, fusing S5 cells, screening and detecting S6, establishing S7 stable cell strain, producing S8 monoclonal antibody, coupling S9 antibody and screening S10 pairing antibody; the polypeptide is respectively synthesized by different antigen epitopes at two ends of the N protein to be used as the antigen, the prepared monoclonal antibody can realize direct pairing, in the process of polypeptide synthesis, a connecting bridge is added to reduce steric hindrance, so that the antigen epitopes are fully exposed on the surface of the carrier protein, the antigen can be quickly identified, the recombinant protein is selected as the detection antigen, the situation that the polypeptide antigen is only identified by the antibody obtained by screening, the risk of the N protein is not identified is avoided, and whether the novel coronavirus is contained in a sample can be directly detected by detecting the content of the N protein.
Description
Technical Field
The invention belongs to the technical field of monoclonal antibody preparation, and particularly relates to a preparation method of a novel coronavirus nucleocapsid protein monoclonal antibody.
Background
Since 12 months in 2019, a plurality of cases of pneumonia with unknown reasons are discovered in succession, and the pneumonia is proved to be an acute respiratory infectious disease caused by novel coronavirus infection. Based on current epidemiological investigations, the latency period is generally 3-7 days, and the maximum period is not more than 14 days. The clinical manifestations of this epidemic disease mainly include fever, hypodynamia and dry cough. A few patients have nasal obstruction, watery nasal discharge, diarrhea, etc. Some patients only show low fever, slight hypodynamia and the like, have no appearance of the pneumonia, and recover after 1 week mostly, the world health organization names a pathogen causing the viral pneumonia case to be a 2019 novel coronavirus, namely SARS-CoV-2 virus, and nucleocapsid protein (N protein) is the most abundant protein in the coronavirus.
The detection antibody used in the existing novel coronavirus detection kit can not realize direct pairing, and in the preparation process of the detection antibody, because the antigen epitope is not fully exposed, the speed of antigen recognition is reduced, and simultaneously, when the detection antibody is prepared, coronavirus is used as the antigen, and the coronavirus is easily combined with N protein to form the spiral nucleocapsid protein, so that the accuracy of the detection result is reduced.
Disclosure of Invention
The invention aims to provide a preparation method of a novel coronavirus nucleocapsid protein monoclonal antibody.
The technical problems to be solved by the invention are as follows:
the detection antibody used in the existing novel coronavirus detection kit can not realize direct pairing, and in the preparation process of the detection antibody, because the antigen epitope is not fully exposed, the speed of antigen recognition is reduced, and simultaneously, when the detection antibody is prepared, coronavirus is used as the antigen, and the coronavirus is easily combined with N protein to form the spiral nucleocapsid protein, so that the accuracy of the detection result is reduced.
The purpose of the invention can be realized by the following technical scheme:
a preparation method of a novel coronavirus nucleocapsid protein monoclonal antibody specifically comprises the following steps:
1 polypeptide synthesis: synthesizing a polypeptide with 15 amino acid sequences at the N end of the N protein, adding a connecting bridge and a carrier protein binding site to prepare an NP-N polypeptide, synthesizing a polypeptide with an aa383-aa394 sequence at the C end of the N protein, and adding a connecting bridge and a carrier protein binding site to prepare an NP-C polypeptide;
2, immunogen preparation: after activating keyhole limpet hemocyanin by maleimide, respectively reacting NP-N polypeptide and NP-C polypeptide with the activated keyhole limpet hemocyanin for 2h at room temperature to prepare KLH-NP-N immunogen and KLH-NP-C immunogen;
3 preparation of screening antigen: constructing an N protein prokaryotic expression vector, adding 6-His tag to the C end of the expression vector, and expressing and purifying to prepare NP-His screening antigen;
4, animal immunization: respectively immunizing Balb/C mice with KLH-NP-N immunogen and KLH-NP-C immunogen, wherein each Balb/C mouse is immunized with 100ug each time for 3 times, and the interval time is two weeks each time;
5, cell fusion: 1 week after the third immunization, respectively taking spleens of mice in groups of KLH-NP-N and KLH-NP-C, separating splenocytes into single cell suspensions, mixing the single cell suspensions with mouse myeloma cells SP2/0 in logarithmic phase according to the ratio of 1:1, performing cell fusion by using a cell fusion instrument, plating fused cells in groups of KLH-NP-N and KLH-NP-C into a 96-hole cell culture plate, adding HAT screening reagent, and performing primary complete liquid exchange after culturing for 5 days;
6, screening and detecting: coating NP-His screening antigen into an enzyme label plate, respectively carrying out indirect ELISA screening on cell supernatant after KLH-NP-N, KLH-NP-C group fusion by using the NP-His screening antigen, and reserving positive clones;
7 establishment of stable cell lines: carrying out subcloning on the positive clone until the positive detection rate is 100%, carrying out expanded culture and freezing and preserving seeds to obtain a hybridoma stable cell strain;
8 monoclonal antibody production: culturing the hybridoma stable cell strain by serum-free fermentation, collecting cell culture supernatant, and performing affinity purification on the monoclonal antibody by Prontein A to obtain a primary N protein monoclonal antibody;
9 antibody coupling: coupling the monoclonal antibody with horseradish peroxidase by using a simple sodium periodate method to obtain a labeled antibody;
10 paired antibody screening: and (3) coating the unmarked antibody into an ELISA plate as a capture antibody, adding the diluted NP-His screening antigen into the ELISA plate, culturing, adding the labeled antibodies in pairs for pairing detection, and screening positive holes to obtain the nucleocapsid protein paired monoclonal antibody pair.
Further, the NP-N polypeptide sequence is as follows: MSDNGPQNQRNAPRIGGGGSC, NP-C polypeptide is listed as: PQRQKKQQTVTLGGGGSC, NP-N polypeptide and activated keyhole limpet hemocyanin at a ratio of 1:1, and NP-C polypeptide and activated keyhole limpet hemocyanin at a ratio of 1: 1.
Further, the specific steps of animal immunization are as follows: mixing KLH-NP-N immunogen and Freund's complete adjuvant according to the mass ratio of 1:1 to prepare first mixed solution, mixing KLH-NP-C immunogen and Freund's complete adjuvant according to the mass ratio of 1:1 to prepare second mixed solution, performing subcutaneous injection on 6-week-old Balb/C mice respectively by using the first mixed solution and the second mixed solution, wherein the number of injection sites is 6, and the injection amount is 100 mu g per time to obtain primary-immunized mice, mixing KLH-NP-N immunogen and Freund's incomplete adjuvant according to the mass ratio of 1:1 to prepare third mixed solution, mixing KLH-NP-C immunogen and Freund's incomplete adjuvant according to the mass ratio of 1:1 to prepare fourth mixed solution, repeating immunization on the mice which are immunized for two weeks for 2 times respectively by using the third mixed solution and the fourth mixed solution, two weeks apart.
Further, the specific steps of cell fusion are as follows: respectively taking spleens of mice in groups of KLH-NP-N and KLH-NP-C1 week after three times of immunization, putting the spleens of the mice into a culture dish containing 5ml of MEM liquid, crushing the spleens, filtering the spleen by using a nylon net to obtain single cell suspension, mixing the single cell suspension and cell liquid of mouse myeloma cells SP2/0 in a logarithmic phase according to the volume ratio of 1:1, performing cell fusion by using a cell fusion instrument, paving fused cells into a 96-hole cell culture plate, adding HAT screening reagent, and performing total liquid change after culturing for 5 days.
Further, the detection and screening comprises the following specific steps: the method comprises the steps of coating NP-His screening antigen into an enzyme label plate, carrying out overnight culture at the temperature of 4 ℃, washing with PBST (basic-bound protein) with the pH value of 7.4 for three times, adding a sealing solution at the temperature of 37 ℃ for sealing for 2 hours, then removing the sealing solution and drying at the temperature of 37 ℃, respectively adding 100 mu L of supernatant of KLH-NP-N and KLH-NP-C group fusion cells into the enzyme label plate per hole, carrying out incubation at the temperature of 37 ℃ for 60 minutes, then adding 100 mu L of goat anti-mouse IgG enzyme-labeled secondary antibody with the mass fraction of 0.5 thousandth into the enzyme label plate per hole, carrying out incubation at the temperature of 37 ℃ for 60 minutes, adding 100 mu L of TMB single-component developing solution per hole into the enzyme label plate, carrying out room-temperature action for 20 minutes, then adding 50 mu L of stop solution per hole, carrying out indirect ELISA screening, and retaining positive clones.
Further, the specific steps for establishing the stable cell strain are as follows: and (3) respectively carrying out cloning culture on the hybridoma cells with positive detection by using KLH-NP-N and KLH-NP-C group positive clones by using a limiting dilution method, and screening positive subclones until the positive detection rate is 100% to obtain a hybridoma stable cell strain.
Further, the specific steps of monoclonal antibody production are as follows: respectively culturing hybridoma stable cell strains of KLH-NP-N and KLH-NP-C groups by adopting serum-free fermentation, collecting cell culture supernatant, mixing the supernatant, ProntenA and a phosphate buffer solution with the pH of 7.4, adding the mixture into a chromatographic column, eluting an antibody by using a phosphate buffer solution with the pH of 7.4 as a balance solution and using a citric acid solution with the pH of 4.0, adjusting the pH value to 7.0 by using a Tris-HCl buffer solution with the pH of 9.0, and collecting the antibody to obtain the primary N protein monoclonal antibody.
Further, the specific steps of antibody coupling are as follows:
step A1: dissolving 5mg of horseradish peroxidase in 1mL of deionized beams to prepare a horseradish peroxidase solution, dissolving 241mg of sodium periodate in 10mL of deionized water to prepare a sodium periodate solution, adding the horseradish peroxidase solution into the sodium periodate solution, stirring for 20min at the rotation speed of 200r/min and at the lightproof room temperature to obtain a mixed solution a, adding the mixed solution a into a dialysis bag, and dialyzing a 1mM sodium acetate buffer solution with the pH value of 4.4 overnight at the temperature of 4 ℃ to obtain a mixed solution b;
step A2: adding 20 mu L of 0.2M carbonate buffer solution with the pH value of 9.5 into the mixed solution b prepared in the step A1 to enable the pH value of the hydroformylation HRP to be 9.5, respectively adding 1mL of 6 monoclonal antibodies dissolved in the 0.01M carbonate buffer solution, and stirring for 2h at the room temperature with the rotation speed of 60r/min and in a dark place to prepare 6 groups of mixed solution c 1-mixed solution c 6;
step A3: dissolving 4mg of sodium borohydride in 1mL of deionized water to prepare a sodium borohydride solution, adding the sodium borohydride solution into the mixed solution c 1-mixed solution c6, stirring uniformly, keeping the temperature for 2 hours at 4 ℃, putting the mixture into a dialysis bag, and dialyzing overnight in 0.15M PBS buffer solution with the pH value of 7.4 at 4 ℃ to obtain mixed solution d 1-mixed solution d 6;
step A4: adding an isosomal saturated ammonium sulfate aqueous solution into the mixed solution d 1-mixed solution d6, standing for 1h at the temperature of 4 ℃, centrifuging at the rotation speed of 3000r/min, removing supernatant, washing a substrate twice with a half-saturated ammonium sulfate aqueous solution, dissolving the substrate in PBS with the pH value of 7.4 at 0.15M to prepare a mixed solution e 1-mixed solution e6, respectively filling the mixed solution e 1-mixed solution e6 into dialysis bags, dialyzing with PB buffer saline with the pH value of 7.4 at 0.15M, removing ammonium ions, centrifuging at the rotation speed of 10000r/min for 30min, removing precipitates, and freeze-drying and storing the supernatant.
Further, the specific steps of paired antibody screening are as follows: coating an unlabeled antibody into an ELISA plate as a capture antibody, adding a diluted NP-His screening antigen with the concentration of 10ng/ml into the ELISA plate, incubating for 30min at the temperature of 37 ℃, washing away the unbound NP-His screening antigen by using PBST washing buffer solution, adding an HRP-labeled antibody into the ELISA plate as a detection antibody, incubating for 30min at the temperature of 37 ℃, washing away the unbound labeled antibody by using the PBST washing buffer solution, adding TMB developing solution into the ELISA plate, incubating for 5min at the temperature of 37 ℃, adding 2M sulfuric acid termination solution into the ELISA plate, measuring OD450 reading by using an ELISA reader, and selecting a positive hole to obtain the nucleocapsid protein monoclonal antibody capable of forming sandwich pairing.
The invention has the beneficial effects that: synthesizing polypeptide of 15 amino acid sequences at the N end of the N protein and polypeptide of aa383-aa394 sequences at the C end of the N protein, respectively adding a connecting bridge and a carrier protein combination site to obtain NP-N polypeptide and NP-C polypeptide, respectively reacting the NP-N polypeptide and NP-C polypeptide with activated keyhole limpet hemocyanin to obtain KLH-NP-N immunogen and KLH-NP-C immunogen, simultaneously constructing an N protein prokaryotic expression vector, adding 6 His tag at the C end of the expression vector, expressing and purifying to obtain NP-His screening antigen, respectively immunizing Balb/C mice aged for 6 weeks by using the KLH-NP-N immunogen and the KLH-NP-C immunogen as antigens, after 3 times of immunization, picking the spleen of the mice after one week of impact immunization, preparing spleen single cell suspension, carrying out cell fusion with mouse myeloma cells SP2/0, further culturing the fused cells, carrying out indirect ELISA screening on fused cell supernatant, keeping positive clones, carrying out subcloning on the positive clones to ensure that the positive detection rate is 100% to obtain stable hybridoma cell strains, culturing the stable hybridoma cell strains by serum-free fermentation, collecting cell culture supernatant, carrying out Prontein A affinity purification to obtain primary N protein monoclonal antibodies, coupling the primary N protein monoclonal antibodies with horseradish peroxidase to obtain labeled antibodies, and further carrying out pairing screening on the antibodies to obtain nucleocapsid protein monoclonal antibody pairs. The polypeptide is respectively synthesized by different antigen epitopes at two ends of the N protein to be used as the antigen, the prepared monoclonal antibody can realize direct pairing, in the process of polypeptide synthesis, a connecting bridge is added to reduce steric hindrance, so that the antigen epitopes are fully exposed on the surface of the carrier protein, the antigen can be quickly identified, the recombinant protein is selected as the detection antigen, the situation that the polypeptide antigen is only identified by the antibody obtained by screening, the risk of the N protein is not identified is avoided, and whether the novel coronavirus is contained in a sample can be directly detected by detecting the content of the N protein.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Examples
A preparation method of a novel coronavirus nucleocapsid protein monoclonal antibody specifically comprises the following steps:
1 polypeptide synthesis: synthesizing a polypeptide with 15 amino acid sequences at the N end of the N protein, adding a connecting bridge and a carrier protein binding site to prepare an NP-N polypeptide, synthesizing a polypeptide with an aa383-aa394 sequence at the C end of the N protein, and adding a connecting bridge and a carrier protein binding site to prepare an NP-C polypeptide;
2, immunogen preparation: after activating keyhole limpet hemocyanin by maleimide, respectively reacting NP-N polypeptide and NP-C polypeptide with the activated keyhole limpet hemocyanin for 2h at room temperature to prepare KLH-NP-N immunogen and KLH-NP-C immunogen;
3 preparation of screening antigen: constructing an N protein prokaryotic expression vector, adding 6-His tag to the C end of the expression vector, and expressing and purifying to prepare NP-His screening antigen;
4, animal immunization: mixing KLH-NP-N immunogen and Freund's complete adjuvant according to the mass ratio of 1:1 to prepare first mixed solution, mixing KLH-NP-C immunogen and Freund's complete adjuvant according to the mass ratio of 1:1 to prepare second mixed solution, performing subcutaneous injection on 6-week-old Balb/C mice respectively by using the first mixed solution and the second mixed solution, wherein the number of injection sites is 6, and the injection amount is 100 mu g per time to obtain primary-immunized mice, mixing KLH-NP-N immunogen and Freund's incomplete adjuvant according to the mass ratio of 1:1 to prepare third mixed solution, mixing KLH-NP-C immunogen and Freund's incomplete adjuvant according to the mass ratio of 1:1 to prepare fourth mixed solution, repeating immunization on the mice which are immunized for two weeks for 2 times respectively by using the third mixed solution and the fourth mixed solution, every two weeks;
5, cell fusion: respectively taking spleens of mice in groups of KLH-NP-N and KLH-NP-C1 week after three times of immunization, putting the spleens of the mice into a culture dish containing 5ml of MEM liquid, crushing the spleens, filtering the spleen by using a nylon net to obtain single cell suspension, mixing the single cell suspension and cell liquid of mouse myeloma cells SP2/0 in a logarithmic phase according to the volume ratio of 1:1, performing cell fusion by using a cell fusion instrument, paving fused cells into a 96-hole cell culture plate, adding an HAT screening reagent, and performing primary liquid change after culturing for 5 days;
6, screening and detecting: coating NP-His screening antigen into an enzyme label plate, performing overnight culture at the temperature of 4 ℃, washing with PBST (basic-bound protein) with the pH value of 7.4 for three times, adding a sealing solution at the temperature of 37 ℃ for sealing for 2 hours, then removing the sealing solution, drying at the temperature of 37 ℃, respectively adding 100 mu L of supernatant of KLH-NP-N and KLH-NP-C group fusion cells into the enzyme label plate per hole, incubating at the temperature of 37 ℃ for 60 minutes, then adding 100 mu L of goat anti-mouse IgG enzyme-labeled secondary antibody with the mass fraction of 0.5 per thousand into the enzyme label plate per hole, incubating at the temperature of 37 ℃ for 60 minutes, then adding 100 mu L of TMB single-component developing solution per hole into the enzyme label plate, acting at the room temperature for 20 minutes, adding 50 mu L of stop solution per hole, performing indirect ELISA screening, and keeping positive clones;
7 establishment of stable cell lines: respectively carrying out cloning culture on hybrid tumor cells with positive detection by using KLH-NP-N and KLH-NP-C group positive clones by using a limiting dilution method, and screening positive subclones until the positive detection rate is 100% to obtain a hybrid tumor stable cell strain;
8 monoclonal antibody production: respectively culturing hybridoma stable cell strains of KLH-NP-N and KLH-NP-C groups by adopting serum-free fermentation, collecting cell culture supernatant, mixing the supernatant, Prontein A and a phosphate buffer solution with the pH of 7.4, adding the mixture into a chromatographic column, eluting an antibody by using a phosphate buffer solution with the pH of 7.4 as a balance solution and using a citric acid solution with the pH of 4.0, adjusting the pH value to 7.0 by using a Tris-HCl buffer solution with the pH of 9.0, and collecting the antibody to obtain a primary N protein monoclonal antibody;
9 antibody coupling: step A1: dissolving 5mg of horseradish peroxidase in 1mL of deionized beams to prepare a horseradish peroxidase solution, dissolving 241mg of sodium periodate in 10mL of deionized water to prepare a sodium periodate solution, adding the horseradish peroxidase solution into the sodium periodate solution, stirring for 20min at the rotation speed of 200r/min and at the lightproof room temperature to obtain a mixed solution a, adding the mixed solution a into a dialysis bag, and dialyzing a 1mM sodium acetate buffer solution with the pH value of 4.4 overnight at the temperature of 4 ℃ to obtain a mixed solution b;
step A2: adding 20 mu L of 0.2M carbonate buffer solution with the pH value of 9.5 into the mixed solution b prepared in the step A1 to enable the pH value of the hydroformylation HRP to be 9.5, respectively adding 1mL of 6 monoclonal antibodies dissolved in the 0.01M carbonate buffer solution, and stirring for 2h at the room temperature with the rotation speed of 60r/min and in a dark place to prepare 6 groups of mixed solution c 1-mixed solution c 6;
step A3: dissolving 4mg of sodium borohydride in 1mL of deionized water to prepare a sodium borohydride solution, adding the sodium borohydride solution into the mixed solution c 1-mixed solution c6, stirring uniformly, keeping the temperature for 2 hours at 4 ℃, putting the mixture into a dialysis bag, and dialyzing overnight in 0.15M PBS buffer solution with the pH value of 7.4 at 4 ℃ to obtain mixed solution d 1-mixed solution d 6;
step A4: adding an isosomal saturated ammonium sulfate aqueous solution into the mixed solution d 1-mixed solution d6, standing for 1h at the temperature of 4 ℃, centrifuging at the rotation speed of 3000r/min, removing supernatant, washing a substrate twice by using a half-saturated ammonium sulfate aqueous solution, dissolving the substrate in PBS (0.15M and pH value of 7.4) to prepare a mixed solution e 1-mixed solution e6, respectively filling the mixed solution e 1-mixed solution e6 into dialysis bags, dialyzing at 0.15M and pH value of 7.4 by using PB buffer saline, removing ammonium ions, centrifuging at the rotation speed of 10000r/min for 30min, removing precipitates, and freeze-drying and storing the supernatant;
10 paired antibody screening: the method comprises the steps of coating an unlabeled antibody into an ELISA plate as a capture antibody, adding a diluted NP-His screening antigen with the concentration of 10ng/ml into the ELISA plate, incubating for 30min at the temperature of 37 ℃, washing away the unbound NP-His screening antigen by using PBST washing buffer, adding an HRP-labeled antibody into the ELISA plate as a detection antibody, incubating for 30min at the temperature of 37 ℃, washing away the unbound labeled antibody by using the PBST washing buffer, adding TMB developing solution into the ELISA plate, incubating for 5min at the temperature of 37 ℃, adding 2M sulfuric acid termination solution into the ELISA plate, measuring OD450 readings by using an ELISA reader, selecting positive holes, and recording corresponding antibody pairs, wherein the results are shown in the following table 1.
TABLE 1
The foregoing is merely exemplary and illustrative of the principles of the present invention and various modifications, additions and substitutions of the specific embodiments described herein may be made by those skilled in the art without departing from the principles of the present invention or exceeding the scope of the claims set forth herein.
Claims (9)
1. A preparation method of a novel coronavirus nucleocapsid protein monoclonal antibody is characterized by comprising the following steps: the method specifically comprises the following steps:
1 polypeptide synthesis: synthesizing a polypeptide with 15 amino acid sequences at the N end of the N protein, adding a connecting bridge and a carrier protein binding site to prepare an NP-N polypeptide, synthesizing a polypeptide with an aa383-aa394 sequence at the C end of the N protein, and adding a connecting bridge and a carrier protein binding site to prepare an NP-C polypeptide;
2, immunogen preparation: after activating keyhole limpet hemocyanin by maleimide, respectively reacting NP-N polypeptide and NP-C polypeptide with the activated keyhole limpet hemocyanin for 2h at room temperature to prepare KLH-NP-N immunogen and KLH-NP-C immunogen;
3 preparation of screening antigen: constructing an N protein prokaryotic expression vector, adding 6-His tag to the C end of the expression vector, and expressing and purifying to prepare NP-His screening antigen;
4, animal immunization: respectively immunizing Balb/C mice with KLH-NP-N immunogen and KLH-NP-C immunogen, wherein each Balb/C mouse is immunized with 100ug each time for 3 times, and the interval time is two weeks each time;
5, cell fusion: 1 week after the third immunization, respectively taking spleens of mice in groups of KLH-NP-N and KLH-NP-C, separating splenocytes into single cell suspensions, mixing the single cell suspensions with mouse myeloma cells SP2/0 in logarithmic phase according to the ratio of 1:1, performing cell fusion by using a cell fusion instrument, plating fused cells in groups of KLH-NP-N and KLH-NP-C into a 96-hole cell culture plate, adding HAT screening reagent, and performing primary complete liquid exchange after culturing for 5 days;
6, screening and detecting: coating NP-His screening antigen into an enzyme label plate, respectively carrying out indirect ELISA screening on cell supernatant after KLH-NP-N, KLH-NP-C group fusion by using the NP-His screening antigen, and reserving positive clones;
7 establishment of stable cell lines: carrying out subcloning on the positive clone until the positive detection rate is 100%, carrying out expanded culture and freezing and preserving seeds to obtain a hybridoma stable cell strain;
8 monoclonal antibody production: culturing the hybridoma stable cell strain by serum-free fermentation, collecting cell culture supernatant, and performing affinity purification on the monoclonal antibody by Prontein A to obtain a primary N protein monoclonal antibody;
9 antibody coupling: coupling the monoclonal antibody with horseradish peroxidase by using a simple sodium periodate method to obtain a labeled antibody;
10 paired antibody screening: and (3) coating the unmarked antibody into an ELISA plate as a capture antibody, adding the diluted NP-His screening antigen into the ELISA plate, culturing, adding the labeled antibodies in pairs for pairing detection, and screening positive holes to obtain the nucleocapsid protein paired monoclonal antibody pair.
2. The method for preparing the novel monoclonal antibody against coronavirus nucleocapsid protein according to claim 1, wherein: the NP-N polypeptide sequence is as follows: MSDNGPQNQRNAPRIGGGGSC, NP-C polypeptide is listed as: PQRQKKQQTVTLGGGGSC, NP-N polypeptide and activated keyhole limpet hemocyanin at a ratio of 1:1, and NP-C polypeptide and activated keyhole limpet hemocyanin at a ratio of 1: 1.
3. The method for preparing the novel monoclonal antibody against coronavirus nucleocapsid protein according to claim 1, wherein: the specific steps of animal immunization are as follows: mixing KLH-NP-N immunogen and Freund's complete adjuvant according to the mass ratio of 1:1 to prepare first mixed solution, mixing KLH-NP-C immunogen and Freund's complete adjuvant according to the mass ratio of 1:1 to prepare second mixed solution, performing subcutaneous injection on 6-week-old Balb/C mice respectively by using the first mixed solution and the second mixed solution, wherein the number of injection sites is 6, and the injection amount is 100 mu g per time to obtain primary-immunized mice, mixing KLH-NP-N immunogen and Freund's incomplete adjuvant according to the mass ratio of 1:1 to prepare third mixed solution, mixing KLH-NP-C immunogen and Freund's incomplete adjuvant according to the mass ratio of 1:1 to prepare fourth mixed solution, repeating immunization on the mice which are immunized for two weeks for 2 times respectively by using the third mixed solution and the fourth mixed solution, two weeks apart.
4. The method for preparing the novel monoclonal antibody against coronavirus nucleocapsid protein according to claim 1, wherein: the specific steps of cell fusion are as follows: respectively taking spleens of mice in groups of KLH-NP-N and KLH-NP-C1 week after three times of immunization, putting the spleens of the mice into a culture dish containing 5ml of MEM liquid, crushing the spleens, filtering the spleen by using a nylon net to obtain single cell suspension, mixing the single cell suspension and cell liquid of mouse myeloma cells SP2/0 in a logarithmic phase according to the volume ratio of 1:1, performing cell fusion by using a cell fusion instrument, paving fused cells into a 96-hole cell culture plate, adding HAT screening reagent, and performing total liquid change after culturing for 5 days.
5. The method for preparing the novel monoclonal antibody against coronavirus nucleocapsid protein according to claim 1, wherein: the detection and screening method comprises the following specific steps: the method comprises the steps of coating NP-His screening antigen into an enzyme label plate, carrying out overnight culture at the temperature of 4 ℃, washing with PBST (basic-bound protein) with the pH value of 7.4 for three times, adding a sealing solution at the temperature of 37 ℃ for sealing for 2 hours, then removing the sealing solution and drying at the temperature of 37 ℃, respectively adding 100 mu L of supernatant of KLH-NP-N and KLH-NP-C group fusion cells into the enzyme label plate per hole, carrying out incubation at the temperature of 37 ℃ for 60 minutes, then adding 100 mu L of goat anti-mouse IgG enzyme-labeled secondary antibody with the mass fraction of 0.5 thousandth into the enzyme label plate per hole, carrying out incubation at the temperature of 37 ℃ for 60 minutes, adding 100 mu L of TMB single-component developing solution per hole into the enzyme label plate, carrying out room-temperature action for 20 minutes, then adding 50 mu L of stop solution per hole, carrying out indirect ELISA screening, and retaining positive clones.
6. The method for preparing the novel monoclonal antibody against coronavirus nucleocapsid protein according to claim 1, wherein: the specific steps for establishing the stable cell strain are as follows: and (3) respectively carrying out cloning culture on the hybridoma cells with positive detection by using KLH-NP-N and KLH-NP-C group positive clones by using a limiting dilution method, and screening positive subclones until the positive detection rate is 100% to obtain a hybridoma stable cell strain.
7. The method for preparing the novel monoclonal antibody against coronavirus nucleocapsid protein according to claim 1, wherein: the monoclonal antibody production method specifically comprises the following steps: respectively culturing hybridoma stable cell strains of KLH-NP-N and KLH-NP-C groups by adopting serum-free fermentation, collecting cell culture supernatant, mixing the supernatant, Prontein A and a phosphate buffer solution with the pH of 7.4, adding the mixture into a chromatographic column, eluting an antibody by using a phosphate buffer solution with the pH of 7.4 as a balance solution and using a citric acid solution with the pH of 4.0, adjusting the pH value to 7.0 by using a Tris-HCl buffer solution with the pH of 9.0, and collecting the antibody to obtain the primary N protein monoclonal antibody.
8. The method for preparing the novel monoclonal antibody against coronavirus nucleocapsid protein according to claim 1, wherein: the specific steps of antibody coupling are as follows:
step A1: dissolving 5mg of horseradish peroxidase in 1mL of deionized beams to prepare a horseradish peroxidase solution, dissolving 241mg of sodium periodate in 10mL of deionized water to prepare a sodium periodate solution, adding the horseradish peroxidase solution into the sodium periodate solution, stirring for 20min at the rotation speed of 200r/min and at the lightproof room temperature to obtain a mixed solution a, adding the mixed solution a into a dialysis bag, and dialyzing a 1mM sodium acetate buffer solution with the pH value of 4.4 overnight at the temperature of 4 ℃ to obtain a mixed solution b;
step A2: adding 20 mu L of 0.2M carbonate buffer solution with the pH value of 9.5 into the mixed solution b prepared in the step A1 to enable the pH value of the hydroformylation HRP to be 9.5, respectively adding 1mL of 6 monoclonal antibodies dissolved in the 0.01M carbonate buffer solution, and stirring for 2h at the room temperature with the rotation speed of 60r/min and in a dark place to prepare 6 groups of mixed solution c 1-mixed solution c 6;
step A3: dissolving 4mg of sodium borohydride in 1mL of deionized water to prepare a sodium borohydride solution, adding the sodium borohydride solution into the mixed solution c 1-mixed solution c6, stirring uniformly, keeping the temperature for 2 hours at 4 ℃, putting the mixture into a dialysis bag, and dialyzing overnight in 0.15M PBS buffer solution with the pH value of 7.4 at 4 ℃ to obtain mixed solution d 1-mixed solution d 6;
step A4: adding an isosomal saturated ammonium sulfate aqueous solution into the mixed solution d 1-mixed solution d6, standing for 1h at the temperature of 4 ℃, centrifuging at the rotation speed of 3000r/min, removing supernatant, washing a substrate twice with a half-saturated ammonium sulfate aqueous solution, dissolving the substrate in PBS with the pH value of 7.4 at 0.15M to prepare a mixed solution e 1-mixed solution e6, respectively filling the mixed solution e 1-mixed solution e6 into dialysis bags, dialyzing with PB buffer saline with the pH value of 7.4 at 0.15M, removing ammonium ions, centrifuging at the rotation speed of 10000r/min for 30min, removing precipitates, and freeze-drying and storing the supernatant.
9. The method for preparing the novel monoclonal antibody against coronavirus nucleocapsid protein according to claim 1, wherein: the specific steps of paired antibody screening are as follows: coating an unlabeled antibody into an ELISA plate as a capture antibody, adding a diluted NP-His screening antigen with the concentration of 10ng/ml into the ELISA plate, incubating for 30min at the temperature of 37 ℃, washing away the unbound NP-His screening antigen by using PBST washing buffer solution, adding an HRP-labeled antibody into the ELISA plate as a detection antibody, incubating for 30min at the temperature of 37 ℃, washing away the unbound labeled antibody by using the PBST washing buffer solution, adding TMB developing solution into the ELISA plate, incubating for 5min at the temperature of 37 ℃, adding 2M sulfuric acid termination solution into the ELISA plate, measuring OD450 reading by using an ELISA reader, and selecting a positive hole to obtain the nucleocapsid protein monoclonal antibody capable of forming sandwich pairing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011002612.6A CN112111007A (en) | 2020-09-22 | 2020-09-22 | Preparation method of novel coronavirus nucleocapsid protein monoclonal antibody |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011002612.6A CN112111007A (en) | 2020-09-22 | 2020-09-22 | Preparation method of novel coronavirus nucleocapsid protein monoclonal antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112111007A true CN112111007A (en) | 2020-12-22 |
Family
ID=73800894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011002612.6A Pending CN112111007A (en) | 2020-09-22 | 2020-09-22 | Preparation method of novel coronavirus nucleocapsid protein monoclonal antibody |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112111007A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112679605A (en) * | 2021-03-15 | 2021-04-20 | 安源医药科技（上海）有限公司 | Antibodies or antigen binding fragments thereof against novel coronavirus nucleocapsid proteins and uses thereof |
| CN112940081A (en) * | 2021-04-12 | 2021-06-11 | 江西乐成生物医疗有限公司 | Polypeptide molecule capable of specifically binding novel coronavirus nucleocapsid protein and preparation method thereof |
| CN113150136A (en) * | 2021-04-30 | 2021-07-23 | 杭州贤至生物科技有限公司 | Preparation of novel coronavirus N protein monoclonal antibody |
| CN115785263A (en) * | 2021-09-10 | 2023-03-14 | 广东菲鹏生物有限公司 | Novel crown antibody or antigen binding fragment thereof and application thereof |
| CN117582488A (en) * | 2023-11-22 | 2024-02-23 | 广东省科学院动物研究所 | Polypeptide composition with lipid-lowering effect and application thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1566143A (en) * | 2003-06-25 | 2005-01-19 | 中国科学院上海生命科学研究院 | Antigenic determinant of SARS coronavirus nucleocapsid protein and application thereof |
| KR20070103548A (en) * | 2006-04-19 | 2007-10-24 | 대한민국(관리부서 질병관리본부장) | Monoclonal antibody against nucleocapsid protein of sars coronavirus and the use thereof |
| CN102030824A (en) * | 2009-09-30 | 2011-04-27 | 王虹 | Monoclonal antibody of hepatitis B virus X protein and use thereof |
| CN111153991A (en) * | 2020-02-26 | 2020-05-15 | 北京博奥森生物技术有限公司 | Human SARS-CoV-2 monoclonal antibody and its preparation method and use |
| CN111308072A (en) * | 2020-03-25 | 2020-06-19 | 中山生物工程有限公司 | Colloidal gold immunochromatography kit for rapidly detecting novel coronavirus IgG antibody and preparation method thereof |
-
2020
- 2020-09-22 CN CN202011002612.6A patent/CN112111007A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1566143A (en) * | 2003-06-25 | 2005-01-19 | 中国科学院上海生命科学研究院 | Antigenic determinant of SARS coronavirus nucleocapsid protein and application thereof |
| KR20070103548A (en) * | 2006-04-19 | 2007-10-24 | 대한민국(관리부서 질병관리본부장) | Monoclonal antibody against nucleocapsid protein of sars coronavirus and the use thereof |
| CN102030824A (en) * | 2009-09-30 | 2011-04-27 | 王虹 | Monoclonal antibody of hepatitis B virus X protein and use thereof |
| CN111153991A (en) * | 2020-02-26 | 2020-05-15 | 北京博奥森生物技术有限公司 | Human SARS-CoV-2 monoclonal antibody and its preparation method and use |
| CN111308072A (en) * | 2020-03-25 | 2020-06-19 | 中山生物工程有限公司 | Colloidal gold immunochromatography kit for rapidly detecting novel coronavirus IgG antibody and preparation method thereof |
Non-Patent Citations (4)
| Title |
|---|
| CHI XIANGYANG,ET AL.: "A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2", 《SCIENCE》 * |
| NINA LE BERT，ET AL: "SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls", 《NATURE》 * |
| 杨田田等: "基于新型冠状病毒结构蛋白的诊疗技术的研究进展", 《现代药物与临床》 * |
| 陈新建编: "《免疫学技术在植物科学中的应用》", 30 April 1998, 中国农业大学出版社 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112679605A (en) * | 2021-03-15 | 2021-04-20 | 安源医药科技（上海）有限公司 | Antibodies or antigen binding fragments thereof against novel coronavirus nucleocapsid proteins and uses thereof |
| CN112679605B (en) * | 2021-03-15 | 2021-07-09 | 安源医药科技（上海）有限公司 | Antibodies or antigen binding fragments thereof against novel coronavirus nucleocapsid proteins and uses thereof |
| CN112940081A (en) * | 2021-04-12 | 2021-06-11 | 江西乐成生物医疗有限公司 | Polypeptide molecule capable of specifically binding novel coronavirus nucleocapsid protein and preparation method thereof |
| CN112940081B (en) * | 2021-04-12 | 2022-10-18 | 江西乐成生物医疗有限公司 | Polypeptide molecule capable of specifically binding novel coronavirus nucleocapsid protein and preparation method thereof |
| CN113150136A (en) * | 2021-04-30 | 2021-07-23 | 杭州贤至生物科技有限公司 | Preparation of novel coronavirus N protein monoclonal antibody |
| CN113150136B (en) * | 2021-04-30 | 2022-04-01 | 杭州贤至生物科技有限公司 | Preparation of novel coronavirus N protein monoclonal antibody |
| CN115785263A (en) * | 2021-09-10 | 2023-03-14 | 广东菲鹏生物有限公司 | Novel crown antibody or antigen binding fragment thereof and application thereof |
| CN117582488A (en) * | 2023-11-22 | 2024-02-23 | 广东省科学院动物研究所 | Polypeptide composition with lipid-lowering effect and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112111007A (en) | Preparation method of novel coronavirus nucleocapsid protein monoclonal antibody | |
| CN112175071A (en) | Preparation method of novel coronavirus spike protein monoclonal antibody | |
| CN111153991A (en) | Human SARS-CoV-2 monoclonal antibody and its preparation method and use | |
| CN105695419B (en) | Hybridoma cell strain 4C9 and its anti-His label protein monoclonal antibody of generation | |
| CN113736744B (en) | Digitoxin monoclonal antibody hybridoma cell strain and application thereof | |
| CN101928346A (en) | Monoclonal antibody of anti-human tissue kallikrein and preparation method thereof | |
| WO2022183762A1 (en) | Anti-phenacetin monoclonal antibody hybridoma cell strain ad, and preparation method therefor and use thereof | |
| CN108395476B (en) | Preparation method of pepsinogen I paired monoclonal antibody | |
| CN111943882B (en) | Pythium hapten, artificial antigen and antibody as well as preparation method and application thereof | |
| CN113637081A (en) | Hybridoma cell strain secreting pendimethalin-resistant monoclonal antibody and application thereof | |
| CN111999497A (en) | Enzyme linked immunosorbent assay kit for detecting rabies virus glycoprotein antigen and application thereof | |
| EP0163141B1 (en) | Monoclonal anti-human igg antibody and process for preparing the same | |
| CN114107219A (en) | Hybridoma cell strain capable of secreting chlordimeform monoclonal antibody and application thereof | |
| CN110713986B (en) | Vitamin B strain 1 Monoclonal antibody hybridoma cell strain CBDD and application thereof | |
| CN115806611B (en) | Antibodies against novel coronavirus N proteins and uses thereof | |
| CN114316037B (en) | Antibody m19 of O-type foot-and-mouth disease virus structural protein, preparation method and application | |
| CN109970550A (en) | Sorbic acid haptens, artificial antigen, antibody and its synthetic method and application | |
| CN112480167B (en) | Isocarbophos hapten, artificial antigen and antibody as well as preparation method and application thereof | |
| CN112939873B (en) | Trimethoprim hapten TMPH, artificial antigen, antibody and preparation method and application thereof | |
| CN111499637B (en) | Yohimbine hapten YHA, artificial antigen and antibody thereof, and preparation and application thereof | |
| CN110981963B (en) | Preparation method of monoclonal antibody for replacing anti-rat-rabbit secondary antibody | |
| CN113234146A (en) | Preparation method of coronavirus spike protein monoclonal antibody | |
| CN106701686B (en) | hybridoma cell strain 1A5, secreted anti-sulbactam monoclonal antibody and application | |
| CN105925538B (en) | Hybridoma cell strain, synthetic cannabis sativa resistant monoclonal antibody generated by hybridoma cell strain and application of synthetic cannabis sativa resistant monoclonal antibody | |
| CN115322969B (en) | Anti-dichlormid monoclonal antibody, monoclonal cell strain and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: 239000 No.69, qifushi West Road, Chuzhou economic and Technological Development Zone, Anhui Province Applicant after: General Biology (Anhui) Co.,Ltd. Address before: 239000 No.69, qifushi West Road, Chuzhou economic and Technological Development Zone, Anhui Province Applicant before: GENERAL BIOSYSTEMS (ANHUI), Inc. |
|
| CB02 | Change of applicant information | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201222 |
|
| RJ01 | Rejection of invention patent application after publication |